标题
Advances in emerging drugs for osteosarcoma
作者
关键词
-
出版物
EXPERT OPINION ON EMERGING DRUGS
Volume 20, Issue 3, Pages 495-514
出版商
Informa Healthcare
发表日期
2015-05-29
DOI
10.1517/14728214.2015.1051965
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
- (2015) Li Cheng et al. CURRENT PHARMACEUTICAL DESIGN
- Disialoganglioside GD2 as a therapeutic target for human diseases
- (2015) Maya Suzuki et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
- (2015) Danielle M. Lussier et al. JOURNAL OF IMMUNOTHERAPY
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Genomic Heterogeneity of Osteosarcoma - Shift from Single Candidates to Functional Modules
- (2015) Kathrin Poos et al. PLoS One
- Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
- (2014) Akmal Safwat et al. ACTA ONCOLOGICA
- Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
- (2014) B. Kasper et al. ANNALS OF ONCOLOGY
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) ANNALS OF ONCOLOGY
- Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper
- (2014) P. G. Casali et al. ANNALS OF ONCOLOGY
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†
- (2014) J. S. Whelan et al. ANNALS OF ONCOLOGY
- Expression of programmed death 1 is correlated with progression of osteosarcoma
- (2014) Wenjie Zheng et al. APMIS
- Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors
- (2014) R. C. Brennan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Recent advances in osteosarcoma
- (2014) Sander M Botter et al. CURRENT OPINION IN PHARMACOLOGY
- Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models
- (2014) Emmy D.G. Fleuren et al. INTERNATIONAL JOURNAL OF CANCER
- Pharmacokinetic study of aldoxorubicin in patients with solid tumors
- (2014) Monica M. Mita et al. INVESTIGATIONAL NEW DRUGS
- Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
- (2014) Valeria Sero et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience
- (2014) Bong Sup Song et al. PEDIATRIC BLOOD & CANCER
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
- (2014) Jennifer A. Perry et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
- (2014) Xiang Chen et al. Cell Reports
- Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential
- (2014) Jacson K Shen et al. OncoImmunology
- Effects of endostar combined multidrug chemotherapy in osteosarcoma
- (2013) Meng Xu et al. BONE
- Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
- (2013) E Tavanti et al. BRITISH JOURNAL OF CANCER
- Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma
- (2013) Michael Roth et al. CANCER
- Osteosarcoma treatment – Where do we stand? A state of the art review
- (2013) Anja Luetke et al. CANCER TREATMENT REVIEWS
- Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
- (2013) L. Zhang et al. CLINICAL CANCER RESEARCH
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
- (2013) Maria Manara et al. CURRENT PHARMACEUTICAL DESIGN
- Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
- (2013) Julia L. Glade Bender et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
- (2013) Gemma Gatta et al. LANCET ONCOLOGY
- Genome-wide association study identifies two susceptibility loci for osteosarcoma
- (2013) Sharon A Savage et al. NATURE GENETICS
- Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
- (2013) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- The Efficacy of Abraxane on Osteosarcoma Xenografts in Nude Mice and Expression of Secreted Protein, Acidic and Rich in Cysteine
- (2012) Yongkun Yang et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Perspectives on cancer stem cells in osteosarcoma
- (2012) Upal Basu-Roy et al. CANCER LETTERS
- Efficacy and Safety of Gemcitabine-Docetaxel Combination Therapy for Recurrent or Refractory High-grade Osteosarcoma in China: A Retrospective Study of 18 Patients
- (2012) W.-X. Qi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas
- (2012) Louis Rapkin et al. PEDIATRIC BLOOD & CANCER
- New targets and approaches in osteosarcoma
- (2012) Jonathan Gill et al. PHARMACOLOGY & THERAPEUTICS
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma
- (2011) Lisa Mirabello et al. BMC CANCER
- Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma
- (2011) Rachael E. Windsor et al. CANCER
- Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
- (2011) J. PosthumaDeBoer et al. CLINICAL & EXPERIMENTAL METASTASIS
- Eribulin Mesylate
- (2011) S. Jain et al. CLINICAL CANCER RESEARCH
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
- (2011) Jakob K. Anninga et al. EUROPEAN JOURNAL OF CANCER
- Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
- (2011) Hans Gelderblom et al. EUROPEAN JOURNAL OF CANCER
- Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
- (2011) Anne McTiernan et al. EUROPEAN JOURNAL OF CANCER
- Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
- (2011) Anna Brózik et al. Expert Opinion on Drug Metabolism & Toxicology
- Mechanisms of drug resistance in kinases
- (2011) Rina Barouch-Bentov et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program
- (2011) Stephen T. Keir et al. PEDIATRIC BLOOD & CANCER
- Ewing's sarcoma
- (2010) A. O. Karosas AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process
- (2010) G. Moriceau et al. CANCER RESEARCH
- Genomic Alterations and Allelic Imbalances Are Strong Prognostic Predictors in Osteosarcoma
- (2010) J. Smida et al. CLINICAL CANCER RESEARCH
- Emerging drugs for high-grade osteosarcoma
- (2010) Claudia Maria Hattinger et al. EXPERT OPINION ON EMERGING DRUGS
- Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations
- (2009) W. Yu et al. BIOINFORMATICS
- Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients
- (2009) Berger Massimo et al. CANCER
- Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
- (2009) Ayesha Abdeen et al. CANCER
- Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma
- (2009) Alexander J. Chou et al. CANCER
- Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
- (2009) Csilla Ozvegy-Laczka et al. CURRENT CANCER DRUG TARGETS
- Prognostic factors and outcomes for osteosarcoma: An international collaboration
- (2009) Emilios E. Pakos et al. EUROPEAN JOURNAL OF CANCER
- Novel therapeutic agents for osteosarcoma
- (2009) Kathleen O’Day et al. Expert Review of Anticancer Therapy
- Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
- (2009) Paul A Meyers Expert Review of Anticancer Therapy
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
- (2009) Quan Zhou et al. MEDICAL ONCOLOGY
- ABC Transporters as Potential Targets for Modulation of Drug Resistance
- (2009) L. Gatti et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
- (2009) Ymera Pignochino et al. Molecular Cancer
- High grade osteosarcoma of the extremities metastatic to the lung: Long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005
- (2009) Antonio Briccoli et al. SURGICAL ONCOLOGY-OXFORD
- Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients
- (2008) Stefan S. Bielack et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now